The Technical Analyst
Select Language :
Arrowhead Pharmaceuticals [ARWR]

Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology

Arrowhead Pharmaceuticals Price, Forecast, Insider, Ratings, Fundamentals & Signals

Current Signal: SELL (auto-tracking)

Arrowhead Pharmaceuticals is listed at the  Exchange

3.09% $28.70

America/New_York / 27 mar 2024 @ 16:00


Arrowhead Pharmaceuticals: Main Fundamentals PE comparison

FUNDAMENTALS
MarketCap: 3 555.84 mill
EPS: -2.77
P/E: -10.36
Earnings Date: Apr 29, 2024
SharesOutstanding: 123.90 mill
Avg Daily Volume: 1.645 mill
RATING 2024-03-27
B-
Neutral
RATINGS
Rating CashFlow: Strong Sell
Return On Equity: Strong Sell
Return On Asset: Sell
DE: Strong Buy
P/E: Strong Sell
Price To Book: Strong Buy
QUARTER GROWTHS
3/224/221/232/233/234/23
Revenue
Gr.Profit
Ebit
Asset
Debt
PE RATIO: COMPANY / SECTOR
0.00x
Company: PE -10.36 | sector: PE -3.05
PE RATIO: COMPANY / INDUSTRY
-1.76x
Company: PE -10.36 | industry: PE 5.88
DISCOUNTED CASH FLOW VALUE
$-26.20
(-191.28%) $-54.90
Date: 2024-03-28
Expected Trading Range (DAY)

$ 26.55 - 30.85

( +/- 7.49%)
ATR Model: 14 days

Insider Trading

Date Person Action Amount type
2024-03-20 Lu Hongbo Buy 1 000 Common Stock
2024-03-19 Lu Hongbo Buy 1 000 Common Stock
2024-03-18 Lu Hongbo Buy 1 000 Common Stock
2024-03-15 Lu Hongbo Sell 0 Common Stock
2024-03-06 Myszkowski Kenneth Allen Sell 40 000 Common Stock
INSIDER POWER
17.97
Last 100 transactions
Buy: 1 028 379 | Sell: 688 332

Forecast: 16:00 - $28.73

Live Trading Signals (every 1 min)

Forecast 1: 16:00 - $28.73
Forecast 2: 16:00 - $28.73
Forecast 3: 16:00 - $28.73
SCORE
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Indicator Signals
RSI 21
SMA
Trend
Trend 2
Trend 3
MACD
Volume Signals
Price $28.70 (3.09% )
Volume 0.511 mill
Avg. Vol. 1.645 mill
% of Avg. Vol 31.03 %
Signal 1:
Signal 2:

Today

Intraday chart data with high, low, open and close for Arrowhead Pharmaceuticals Inc

Last 12 Months

Last 12 months chart data with high, low, open and close for Arrowhead Pharmaceuticals Inc

RSI

Intraday RSI14 chart for Arrowhead Pharmaceuticals Inc

Last 10 Buy & Sell Signals For ARWR

0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%

Avg return buy: 0.00 % | Avg return sell: 0.00 %

$1 invested is now $1.00 or 0.00% since Coming Soon

Date Signal @ Closed %
Feb 8 - 15:35sell$31.19N/AActive
Profile picture for
            Arrowhead Pharmaceuticals Inc

ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.

Last 10 Buy Signals

Date Signal @
LRCUSDMar 28 - 08:44$0.390
JUVUSDMar 28 - 08:402.90
MAVUSDMar 28 - 08:380.651
CGOUSDMar 28 - 08:3871.04
FRONTUSDMar 28 - 08:37$1.261
ETHUPUSDMar 28 - 08:3834.73
XTZUSDMar 28 - 08:37$1.381
XAUTUSDMar 28 - 08:35$2 208.64
GASUSDMar 28 - 08:34$6.97
AAVEUSDMar 28 - 08:36$124.81

Latest Press Releases

Latest News

Disclaimer:

"JimStromberg.com" is a research service that provides financial data and technical analysis of publicly traded stocks. All users should speak with their financial advisor before buying or selling any securities. Users should not base their investment decision upon "JimStromberg.com". By using the site you agree and are held liable for your own investment decisions and agree to Terms of Use and Privacy Policy. Please read the full disclaimer here.